December 16, 2017
Add to Twitter
English | عربي
New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer
Tagrisso demonstrated superior progression-free survival (PFS) of 18.9 months compared with 10.2 months for the current standard of care and an encouraging preliminary overall survival benefit